# CuraSen Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curasen-therapeutics

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: www.curasen.com/
- Total disclosed funding: $45M
- Latest round: Series A (Oct 21, 2021)
- Investors on record: 6

## About

Founded in 2017 and based in California, US, CuraSen Therapeutics, Inc. is a biopharmaceutical company that advances science to improve the lives of patients suffering from debilitating conditions like Parkinson's and Alzheimer's diseases. Anthony Ford (CEO), Kathleen Sereda Glaub, Mehrdad Shamloo, and Robert Booth are the co-founders of the company. In October 2023, CuraSen Therapeutics, Inc. raised USD 5.8 million in grant funding from the Alzheimer's Drug Discovery Foundation.

The company’s product pipeline features a range of therapeutic candidates, primarily centered around adrenergic receptor agonists, which are designed to address both cognitive symptoms and disease progression in neurodegenerative conditions. It’s product pipeline encompasses ß2-AR Agonist, which consists of CST-103/CST-107 (clenbuterol/nadolol), which is a fixed-dose combination in development for Parkinson's disease, specifically targeting cognitive symptoms and disease progression; and CST-2032/CST-107 (nadolol), which addresses cognitive symptoms and disease progression in Alzheimer's disease.

The firm also develops a1A-AR Agonist, which comprises CST-2140, which is designed to treat neurogenic orthostatic hypotension (nOH), a condition characterized by a sharp drop in blood pressure upon standing commonly associated with Parkinsonism, and CST-3056, which is being developed for broader neurodegenerative diseases. CuraSen's drugs mainly focus on restoring locus coeruleus, a part of the brain that synthesizes norepinephrine in the human body, since its degeneration serves as the main reason for Alzheimer’s and Parkinson’s diseases.

The company plans to use the October 2023 funding to launch CST-3056, an alpha-1A adrenoceptor (a1A-AR) agonist for the treatment of Alzheimer’s disease.

## Funding rounds

- Series A, Oct 21, 2021, $18M — Pappas Capital
- Series A, Oct 17, 2018, $27M — Alta Partners, Pappas Capital, Johnson & Johnson Innovation, New Leaf Venture Partners, Tekla Capital Management, Longitude Capital

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series A
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series A
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series A
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A